IL113984A - Conjugates of methyltrithio cytotoxic agents compositions containing them and process for their preparation - Google Patents

Conjugates of methyltrithio cytotoxic agents compositions containing them and process for their preparation

Info

Publication number: IL113984A
Authority: IL; Israel
Prior art keywords: conjugates; carrier; methyltrithio; preparation; compositions containing
Prior art date: 1994-06-03

Application number

IL11398495A

Other languages

English (en)

Other versions

IL113984A0 (en

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-03

Filing date

1995-06-01

Publication date

2000-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22962074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL113984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-01 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

1995-06-01 Priority to IL13297495A priority Critical patent/IL132974A/en

1995-06-01 Priority to IL12995395A priority patent/IL129953A/en

1995-10-31 Publication of IL113984A0 publication Critical patent/IL113984A0/xx

1999-05-13 Priority to IL12995399A priority patent/IL129953A0/xx

2000-09-28 Publication of IL113984A publication Critical patent/IL113984A/xx

Links

238000000034 method Methods 0.000 title abstract 2
229940127089 cytotoxic agent Drugs 0.000 title 1
239000002254 cytotoxic agent Substances 0.000 title 1
231100000599 cytotoxic agent Toxicity 0.000 title 1
-1 methyltrithio Chemical group 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003242 anti bacterial agent Substances 0.000 abstract 2
230000000259 anti-tumor effect Effects 0.000 abstract 2
229940088710 antibiotic agent Drugs 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229930189413 Esperamicin Natural products 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 abstract 1
229930195731 calicheamicin Natural products 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
150000002019 disulfides Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000003431 steroids Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Treatments Of Macromolecular Shaped Articles (AREA)
Plural Heterocyclic Compounds (AREA)

IL11398495A 1994-06-03 1995-06-01 Conjugates of methyltrithio cytotoxic agents compositions containing them and process for their preparation IL113984A (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
IL13297495A IL132974A (en)	1994-06-03	1995-06-01	Compounds useful in the synthesis of conjugates of methyltrithio anti-tumour agents
IL12995395A IL129953A (en)	1994-06-03	1995-06-01	Compounds useful in the synthesis of conjugates of methyltrithio anti-tumour agents
IL12995399A IL129953A0 (en)	1994-06-03	1999-05-13	Compounds useful in the synthesis of conjugates of methyltrithio anti-tumour agents

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/253,877 US5773001A (en)	1994-06-03	1994-06-03	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

Publications (2)

Publication Number	Publication Date
IL113984A0 IL113984A0 (en)	1995-10-31
IL113984A true IL113984A (en)	2000-09-28

Family

ID=22962074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11398495A IL113984A (en)	1994-06-03	1995-06-01	Conjugates of methyltrithio cytotoxic agents compositions containing them and process for their preparation

Country Status (20)

Country	Link
US (4)	US5773001A (de)
EP (1)	EP0689845B1 (de)
JP (2)	JP3650165B2 (de)
KR (1)	KR100408376B1 (de)
AT (1)	ATE223234T1 (de)
AU (1)	AU697280B2 (de)
BR (2)	BR1101078A (de)
CA (1)	CA2150785C (de)
CY (1)	CY2334B1 (de)
DE (1)	DE69528016T2 (de)
DK (1)	DK0689845T3 (de)
ES (1)	ES2181752T3 (de)
FI (1)	FI117690B (de)
IL (1)	IL113984A (de)
NO (1)	NO313617B1 (de)
NZ (3)	NZ536440A (de)
PT (1)	PT689845E (de)
SI (1)	SI0689845T1 (de)
TW (1)	TW394778B (de)
ZA (1)	ZA954570B (de)

Families Citing this family (767)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en) *	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) *	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
AU2335899A (en) *	1998-01-29	1999-08-16	Pharmacopeia, Inc.	Acid cleavable phenoxyalkyl linker for combinatorial synthesis
US6008321A (en) *	1998-03-16	1999-12-28	Pharmacopeia, Inc.	Universal linker for combinatorial synthesis
US6914130B2 (en) *	1998-06-17	2005-07-05	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US6733998B1 (en)	1998-12-07	2004-05-11	Sloan-Kettering Institute For Cancer Research	Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US20050159588A1 (en) *	1999-06-02	2005-07-21	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
ES2329437T3 (es)	1999-06-25	2009-11-26	Genentech, Inc.	Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2.
US20060228364A1 (en) *	1999-12-24	2006-10-12	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) *	2002-06-28	2005-12-29	Genentech, Inc.	Serum albumin binding peptides for tumor targeting
WO2001045746A2 (en) *	1999-12-24	2001-06-28	Genentech, Inc.	Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) *	2002-06-28	2004-01-01	Dennis Mark S.	Serum albumin binding peptides for tumor targeting
WO2001054732A1 (en) *	2000-01-27	2001-08-02	Genetics Institute, Llc.	Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
LT2857516T (lt)	2000-04-11	2017-09-11	Genentech, Inc.	Multivalentiniai antikūnai ir jų panaudojimas
KR20030074680A (ko)	2000-12-28	2003-09-19	와이어쓰	스트렙토코커스 뉴모니에 유래 재조합 보호 단백질
US6652853B2 (en) *	2001-03-08	2003-11-25	Ludwig Institute For Cancer Research	Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
NZ511705A (en) *	2001-05-14	2004-03-26	Horticulture & Food Res Inst	Methods and rapid immunoassay device for detecting progesterone and other steroids
MXPA03011094A (es) *	2001-05-31	2004-12-06	Medarex Inc	Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
US20070160576A1 (en)	2001-06-05	2007-07-12	Genentech, Inc.	IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2372321T3 (es)	2001-06-20	2012-01-18	Genentech, Inc.	Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
US20050107595A1 (en) *	2001-06-20	2005-05-19	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en)	2001-06-20	2010-09-28	Genentech, Inc.	Antibody compositions for the diagnosis and treatment of tumor
US20040086504A1 (en) *	2001-06-21	2004-05-06	Deepak Sampath	Cyr61 as a target for treatment and diagnosis of breast cancer
US20040235068A1 (en) *	2001-09-05	2004-11-25	Levinson Arthur D.	Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ATE486092T1 (de) *	2001-09-18	2010-11-15	Genentech Inc	Zusammensetzungen und verfahren für die diagnose von tumoren
US20040023910A1 (en) *	2001-09-28	2004-02-05	Zhiming Zhang	Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
US20110045005A1 (en) *	2001-10-19	2011-02-24	Craig Crowley	Compositions and methods for the treatment of tumor of hematopoietic origin
US20030228319A1 (en)	2002-04-16	2003-12-11	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
AU2002367318B2 (en)	2002-01-02	2007-07-12	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
US20090042291A1 (en) *	2002-03-01	2009-02-12	Xencor, Inc.	Optimized Fc variants
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US8093357B2 (en) *	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
US20100311954A1 (en) *	2002-03-01	2010-12-09	Xencor, Inc.	Optimized Proteins that Target Ep-CAM
SG187991A1 (en)	2002-05-02	2013-03-28	Wyeth Corp	Calicheamicin derivative-carrier conjugates
PT1585966E (pt)	2002-07-15	2012-02-20	Hoffmann La Roche	Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
SI2345671T1 (sl)	2002-09-27	2016-03-31	Xencor Inc.	Optimizirane Fc-variante in postopki za njihovo izdelavo
ES2641525T3 (es)	2002-10-16	2017-11-10	Purdue Pharma L.P.	Anticuerpos que se unen a CA 125/0722P asociado a células y métodos de uso de los mismos
US20040152632A1 (en) *	2002-11-06	2004-08-05	Wyeth	Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US8388955B2 (en) *	2003-03-03	2013-03-05	Xencor, Inc.	Fc variants
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
MXPA06000347A (es)	2003-07-08	2006-03-28	Genentech Inc	Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
AU2004261459B2 (en)	2003-07-22	2008-06-26	Astex Therapeutics Limited	3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
WO2005086612A2 (en) *	2003-07-29	2005-09-22	Immunomedics, Inc.	Fluorinated carbohydrate conjugates
CA2534055A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody cdr polypeptide sequences with restricted diversity
US9714282B2 (en)	2003-09-26	2017-07-25	Xencor, Inc.	Optimized Fc variants and methods for their generation
US8101720B2 (en) *	2004-10-21	2012-01-24	Xencor, Inc.	Immunoglobulin insertions, deletions and substitutions
US20050282168A1 (en) *	2003-09-29	2005-12-22	Wyeth	Cell surface molecules as markers and therapeutic agents against kidney cancers
NZ583292A (en)	2003-11-06	2012-03-30	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
AU2004291141B2 (en)	2003-11-17	2009-06-11	Genentech, Inc.	Compositions and methods for the treatment of tumor of hematopoietic origin
PT1718677E (pt)	2003-12-19	2012-07-18	Genentech Inc	Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
AR048098A1 (es) *	2004-03-15	2006-03-29	Wyeth Corp	Conjugados de caliqueamicina
NZ550217A (en) *	2004-03-31	2009-11-27	Genentech Inc	Humanized anti-TGF-beta antibodies
ES2549077T3 (es) *	2004-04-07	2015-10-22	Genentech, Inc.	Espectrometría de masas de conjugados de anticuerpos
NZ550934A (en) *	2004-05-19	2010-05-28	Medarex Inc	Chemical linkers and conjugates thereof
US7691962B2 (en) *	2004-05-19	2010-04-06	Medarex, Inc.	Chemical linkers and conjugates thereof
KR101200133B1 (ko)	2004-06-01	2012-11-13	제넨테크, 인크.	항체 약물 접합체 및 방법
AU2005272993B2 (en)	2004-07-15	2010-02-11	Xencor, Inc.	Optimized Fc variants
ES2339789T3 (es)	2004-07-20	2010-05-25	Genentech, Inc.	Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
US7432044B2 (en)	2004-07-26	2008-10-07	Genentech, Inc.	Methods and compositions for modulating hepatocyte growth factor activation
CA2486285C (en) *	2004-08-30	2017-03-07	Viktor S. Goldmakher	Immunoconjugates targeting syndecan-1 expressing cells and use thereof
PL2990422T3 (pl) *	2004-09-03	2018-11-30	Genentech, Inc.	Humanizowani antagoniści anty-beta7 i ich zastosowania
MX2007002826A (es) *	2004-09-10	2007-04-27	Wyeth Corp	Anticuerpos anti-5t4 humanizados y conjugados de anticuerpos anti-5t4/caliqueamicina.
EP1791565B1 (de)	2004-09-23	2016-04-20	Genentech, Inc.	Zystein-modifizierte Antikörper und Konjugate
AU2005294723A1 (en) *	2004-10-05	2006-04-20	Genentech, Inc.	Therapeutic agents with decreased toxicity
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
US8546543B2 (en)	2004-11-12	2013-10-01	Xencor, Inc.	Fc variants that extend antibody half-life
EP2332985A3 (de)	2004-11-12	2012-01-25	Xencor, Inc.	Fc-Varianten mit modifizierter Bindung an fcrn
US20070135620A1 (en) *	2004-11-12	2007-06-14	Xencor, Inc.	Fc variants with altered binding to FcRn
EP1817059A2 (de)	2004-12-01	2007-08-15	Genentech, Inc.	Konjugate von 1,8-bis-naphthalimiden mit einem antikörper
ATE462726T1 (de)	2005-01-07	2010-04-15	Diadexus Inc	Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
KR101346886B1 (ko)	2005-01-21	2014-01-02	아스텍스 테라퓨틱스 리미티드	제약 화합물
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
RU2436575C2 (ru) *	2005-01-21	2011-12-20	Астекс Терапьютикс Лимитед	Соединения для использования в фармацевтике
CA2592177A1 (en)	2005-01-21	2006-07-27	Genentech, Inc.	Fixed dosing of her antibodies
AR054425A1 (es)	2005-01-21	2007-06-27	Astex Therapeutics Ltd	Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
HRP20120709T1 (hr) *	2005-02-18	2012-10-31	Medarex, Inc.	Humano monoklonsko protutijelo za prostata-specifiäśni membranski antigen (psma)
ZA200707078B (en)	2005-02-23	2008-11-26	Genentech Inc	Extending time to disease progression or survival in cancer patients
WO2006096861A2 (en) *	2005-03-08	2006-09-14	Genentech, Inc.	METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
AU2006235258A1 (en)	2005-04-07	2006-10-19	Novartis Vaccines And Diagnostics Inc.	Cancer-related genes
EP1865981A2 (de)	2005-04-07	2007-12-19	Chiron Corporation	Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
US7714016B2 (en) *	2005-04-08	2010-05-11	Medarex, Inc.	Cytotoxic compounds and conjugates with cleavable substrates
EP1871163A2 (de)	2005-06-06	2008-01-02	Genentech, Inc.	Transgene tiermodelle und deren verwendung zur gencharakterisierung
US20070003559A1 (en) *	2005-07-01	2007-01-04	Wyeth	Methods of determining pharmacokinetics of targeted therapies
US7557190B2 (en)	2005-07-08	2009-07-07	Xencor, Inc.	Optimized proteins that target Ep-CAM
JP2009504183A (ja)	2005-08-15	2009-02-05	ジェネンテック・インコーポレーテッド	遺伝子破壊、それに関連する組成物および方法
US8795674B2 (en)	2005-09-30	2014-08-05	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods and compositions for modulating immune tolerance
CA2624189A1 (en)	2005-10-03	2007-04-12	Xencor, Inc.	Fc variants with optimized fc receptor binding properties
AU2006305842B2 (en)	2005-10-26	2011-11-03	E. R. Squibb & Sons, L.L.C.	Methods and compounds for preparing CC-1065 analogs
EP2465870A1 (de)	2005-11-07	2012-06-20	Genentech, Inc.	Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
CA2627190A1 (en)	2005-11-10	2007-05-24	Medarex, Inc.	Duocarmycin derivatives as novel cytotoxic compounds and conjugates
AU2006335053A1 (en)	2005-11-21	2007-07-19	Genentech, Inc.	Novel gene disruptions, compositions and methods relating thereto
EP1973951A2 (de) *	2005-12-02	2008-10-01	Genentech, Inc.	Bindende polypeptide mit eingeschränkten diversitätssequenzen
EP2623516B1 (de)	2005-12-02	2015-07-15	Genentech, Inc.	Zusammensetzungen und Verfahren für die Behandlung von Krankheiten und Störungen in Zusammenhang mit der Zytokinsignalisierung, mit Antikörper, die an IL-22 und IL-22R bind.
RU2470941C2 (ru) *	2005-12-02	2012-12-27	Дженентек, Инк.	Связывающие полипептиды и их применения
AU2006321975A1 (en) *	2005-12-06	2007-06-14	Wyeth	Interleukin-11 compositions and methods of use
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
RU2450020C2 (ru)	2006-01-05	2012-05-10	Дженентек, Инк.	АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2638821A1 (en)	2006-02-17	2007-10-11	Genentech, Inc.	Gene disruptons, compositions and methods relating thereto
AU2012261705B2 (en) *	2006-02-21	2014-02-06	Wyeth Llc	Processes for the convergent synthesis of calicheamicin derivatives
TW200806685A (en) *	2006-02-21	2008-02-01	Wyeth Corp	Processes for the convergent synthesis of calicheamicin derivatives
AU2014202414B2 (en) *	2006-02-21	2016-06-02	Wyeth Llc	Processes for the convergent synthesis of calicheamicin derivatives
EP2946786A1 (de)	2006-03-08	2015-11-25	Wake Forest University Health Sciences	Lösliches monomeres Ephrin-A1
WO2007106744A2 (en)	2006-03-10	2007-09-20	Wyeth	Anti-5t4 antibodies and uses thereof
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
SG170728A1 (en)	2006-03-23	2011-05-30	Novartis Ag	Anti-tumor cell antigen antibody therapeutics
CA2647277A1 (en)	2006-04-05	2007-11-08	Genentech, Inc.	Method for using boc/cdo to modulate hedgehog signaling
KR20090010194A (ko)	2006-04-13	2009-01-29	노바티스 백신즈 앤드 다이아그노스틱스, 인크.	암의 치료, 진단 또는 검출 방법
EP2010662A2 (de)	2006-04-19	2009-01-07	Genentech, Inc.	Neuartige genunterbrechungen, dazugehörige zusammensetzungen und verfahren
WO2007134132A2 (en) *	2006-05-12	2007-11-22	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
PL2032606T3 (pl)	2006-05-30	2014-04-30	Genentech Inc	Przeciwciała i immunokoniugaty oraz ich zastosowania
SI2383297T1 (sl)	2006-08-14	2013-06-28	Xencor Inc.	Optimizirana antitelesa, ki ciljajo cd19
WO2008033782A2 (en)	2006-09-12	2008-03-20	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
JP5528807B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
JP5528806B2 (ja)	2006-10-12	2014-06-25	アステックス、セラピューティックス、リミテッド	複合薬剤
NZ576132A (en)	2006-10-27	2012-04-27	Genentech Inc	Antibodies and immunoconjugates and uses therefor
EP2104513B1 (de)	2006-11-27	2015-05-20	diaDexus, Inc.	Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
TWI412367B (zh)	2006-12-28	2013-10-21	Medarex Llc	化學鏈接劑與可裂解基質以及其之綴合物
NZ578701A (en)	2007-02-09	2012-02-24	Genentech Inc	Anti-robo4 antibodies and uses therefor
CN101616911A (zh)	2007-02-21	2009-12-30	梅达莱克斯公司	具有单个氨基酸的化学连接物及其偶联物
DK2132573T3 (da)	2007-03-02	2014-07-14	Genentech Inc	Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
EP2474556A3 (de)	2007-03-14	2012-10-17	Novartis AG	APCDD1-Inhibitoren zur Behandlung, Diagnose und Erkennung von Krebs
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
SI2155248T1 (sl)	2007-04-12	2015-12-31	The Brigham And Women's Hospital, Inc.	Ciljanje ABCB5 za zdravljenje raka
LT2176298T (lt)	2007-05-30	2018-04-10	Xencor, Inc.	Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9845355B2 (en)	2007-07-16	2017-12-19	Genentech, Inc.	Humanized anti-CD79b antibodies and immunoconjugates and methods of use
RU2511410C3 (ru)	2007-07-16	2021-06-15	Дженентек, Инк.	АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
SG193868A1 (en)	2007-09-26	2013-10-30	Chugai Pharmaceutical Co Ltd	Modified antibody constant region
CA2699601A1 (en)	2007-10-02	2009-04-09	Genentech, Inc.	Nlrr-1 antagonists and uses thereof
US20110033476A1 (en) *	2007-11-12	2011-02-10	Theraclone Sciences Inc.	Compositions and methods for the therapy and diagnosis of influenza
ES2395784T3 (es)	2007-11-12	2013-02-15	Theraclone Sciences, Inc.	Composiciones y métodos para la terapia y diagnosis de la influenza
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
DK2242772T3 (en) *	2007-12-26	2015-01-05	Biotest Ag	Immunoconjugates that targets CD138, and uses thereof
JP2011507933A (ja) *	2007-12-26	2011-03-10	バイオテスト・アクチエンゲゼルシヤフト	免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法
CN101945892B (zh) *	2007-12-26	2017-11-24	生物测试股份公司	用于改进对表达cd138的肿瘤细胞的靶向的方法和试剂
KR101626416B1 (ko) *	2007-12-26	2016-06-01	바이오테스트 아게	Ｃｄ138 표적 물질 및 이의 용도
DK2235059T3 (en)	2007-12-26	2015-03-30	Xencor Inc	FC-VERSIONS OF MODIFIED BINDING TO FcRn
US20110033378A1 (en)	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CA2713504A1 (en)	2008-01-31	2009-08-13	Genentech, Inc.	Anti-cd79b antibodies and immunoconjugates and methods of use
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
MX2010009885A (es)	2008-03-10	2010-11-30	Theraclone Sciences Inc	Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
KR20100131003A (ko) *	2008-03-31	2010-12-14	제넨테크, 인크.	천식을 치료 및 진단하기 위한 조성물 및 방법
SI2279412T1 (sl)	2008-04-09	2017-10-30	Genentech, Inc.,	Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
AU2009246071B2 (en) *	2008-05-16	2013-10-03	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
DK2318832T3 (da)	2008-07-15	2014-01-20	Academia Sinica	Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
EP2323679A4 (de)	2008-07-25	2012-08-22	Univ Colorado	Clip-hemmer und verfahren zur modulierung der immunfunktion
WO2010039832A1 (en)	2008-10-01	2010-04-08	Genentech, Inc.	Anti-notch2 antibodies and methods of use
US20120027722A1 (en)	2008-12-17	2012-02-02	Medical Research Council	Hepatitis c virus combination therapy
JP5936112B2 (ja)	2009-02-11	2016-06-15	アルブミディクスアクティーゼルスカブ	アルブミン変異体及び複合体
SI3260136T1 (sl)	2009-03-17	2021-05-31	Theraclone Sciences, Inc.	Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
WO2010108127A1 (en)	2009-03-20	2010-09-23	Genentech, Inc.	Bispecific anti-her antibodies
AR075925A1 (es)	2009-03-25	2011-05-04	Genentech Inc	Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
HRP20150965T1 (hr) *	2009-03-25	2015-11-06	Genentech, Inc.	Anti-fgr3 protutijela i metode koje ih koriste
TW201038286A (en)	2009-04-01	2010-11-01	Genentech Inc	Anti-FcRH5 antibodies and immunoconjugates and methods of use
JP5501439B2 (ja)	2009-04-02	2014-05-21	ロシュグリクアートアクチェンゲゼルシャフト	完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
KR20110138412A (ko)	2009-04-16	2011-12-27	애보트 바이오테라퓨틱스 코포레이션	항-ΤΝＦ-α 항체 및 그의 용도
WO2010121125A1 (en)	2009-04-17	2010-10-21	Wake Forest University Health Sciences	Il-13 receptor binding peptides
CN102459340A (zh) *	2009-04-23	2012-05-16	特罗科隆科学有限公司	粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
WO2010126551A1 (en)	2009-04-30	2010-11-04	Immunogen, Inc.	Potent conjugates and hydrophilic linkers
AU2010249787A1 (en)	2009-05-20	2011-12-22	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
EP2896404B1 (de)	2009-06-04	2017-08-02	Novartis AG	Verfahren zur Identifizierung von Stellen für IgG-Konjugation
ES2534355T3 (es)	2009-06-17	2015-04-21	Abbvie Biotherapeutics Inc.	Anticuerpos anti-VEGF y sus usos
WO2011005481A1 (en)	2009-06-22	2011-01-13	Medimmune, Llc	ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
SG178177A1 (en)	2009-07-31	2012-03-29	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
SG10201408401RA (en)	2009-09-16	2015-01-29	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
HUE026447T2 (en)	2009-10-16	2016-05-30	Novartis Ag	Pharmacodynamic tumor response biomarkers
JP5889794B2 (ja)	2009-10-19	2016-03-22	ジェネンテック，インコーポレイテッド	肝細胞増殖因子アクチベーターの調節
BR112012009409A2 (pt)	2009-10-22	2017-02-21	Genentech Inc	método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
NZ599337A (en)	2009-10-22	2013-05-31	Genentech Inc	Anti-hepsin antibodies and methods using same
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
ES2639056T3 (es)	2009-10-28	2017-10-25	Abbvie Biotherapeutics Inc.	Anticuerpos anti-EGFR y sus usos
BR112012009450A2 (pt)	2009-10-30	2017-05-23	Novozymes Biopharma Dk As	variantes de albumina
MX2012005168A (es)	2009-11-05	2012-06-08	Genentech Inc	Metodos y composicion para secrecion de polipeptidos heterologos.
SG10201408598XA (en)	2009-11-30	2015-02-27	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
KR20120123299A (ko)	2009-12-04	2012-11-08	제넨테크, 인크.	다중특이적 항체, 항체 유사체, 조성물 및 방법
JP5677451B2 (ja)	2009-12-10	2015-02-25	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用
ES2565208T3 (es)	2009-12-11	2016-04-01	F. Hoffmann-La Roche Ag	Anticuerpos anti-VEGF-C y métodos de uso de los mismos
WO2011084496A1 (en)	2009-12-16	2011-07-14	Abbott Biotherapeutics Corp.	Anti-her2 antibodies and their uses
SI2516468T1 (sl)	2009-12-23	2016-06-30	Synimmune Gmbh	Protitelesa proti flt3 in postopki uporabe istih
TW201130971A (en)	2009-12-23	2011-09-16	Genentech Inc	Anti-Bv8 antibodies and uses thereof
WO2011089211A1 (en)	2010-01-22	2011-07-28	Synimmune Gmbh	Anti-cd133 antibodies and methods of using the same
CN106995493B (zh)	2010-02-04	2021-09-24	卫材公司	氯毒素多肽和结合物及其应用
MX2012008884A (es)	2010-02-08	2012-08-31	Agensys Inc	Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b.
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
NZ601293A (en)	2010-02-23	2014-10-31	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
KR101656548B1 (ko)	2010-03-05	2016-09-09	에프. 호프만-라 로슈 아게	인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
EP2542588A1 (de)	2010-03-05	2013-01-09	F. Hoffmann-La Roche AG	Antikörper gegen menschliches csf-1r und deren verwendungen
TW201134481A (en)	2010-03-12	2011-10-16	Abbott Biotherapeutics Corp	CTLA4 proteins and their uses
RU2587625C2 (ru)	2010-03-24	2016-06-20	Дженентек, Инк.	Анти-lrp6 антитела
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
US10233228B2 (en)	2010-04-09	2019-03-19	Albumedix Ltd	Albumin derivatives and variants
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
MX346731B (es)	2010-04-23	2017-03-30	Genentech Inc *	Producción de proteínas heteromultiméricas.
RU2636461C2 (ru)	2010-05-03	2017-11-23	Дженентек, Инк.	Композиции и способы для диагностики и лечения опухоли
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
RU2613886C2 (ru)	2010-06-03	2017-03-21	Дженентек, Инк.	Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
KR101839163B1 (ko)	2010-06-08	2018-03-15	제넨테크, 인크.	시스테인 조작된 항체 및 접합체
KR101885388B1 (ko)	2010-06-18	2018-08-03	제넨테크, 인크.	항-Ａｘｌ 항체 및 사용 방법
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
US8637641B2 (en)	2010-07-29	2014-01-28	Xencor, Inc.	Antibodies with modified isoelectric points
BR112013002535A2 (pt)	2010-08-03	2019-09-24	F. Hoffmann - La Roche Ag	biomarcadores de leucemia linfocítica crônica (cll)
WO2012021786A2 (en)	2010-08-12	2012-02-16	Theraclone Sciences, Inc.	Anti-hemagglutinin antibody compositions and methods of use thereof
KR101653030B1 (ko)	2010-08-13	2016-08-31	로슈 글리카트 아게	항-테나신-c a２ 항체 및 이의 사용 방법
EA034742B1 (ru)	2010-08-13	2020-03-16	Роше Гликарт Аг	Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения
MX2013001267A (es)	2010-08-13	2013-04-10	Genentech Inc	ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
WO2012025530A1 (en)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP2013537966A (ja)	2010-08-31	2013-10-07	ジェネンテック，インコーポレイテッド	バイオマーカー及び治療の方法
EP2611465A4 (de)	2010-08-31	2014-06-04	Theraclone Sciences Inc	Antikörper zur neutralisierung des humanen immundefizienzvirus (hiv)
WO2012034039A2 (en)	2010-09-10	2012-03-15	Apexigen, Inc.	Anti-il-1 beta antibodies and methods of use
US8637642B2 (en)	2010-09-29	2014-01-28	Seattle Genetics, Inc.	Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9228023B2 (en)	2010-10-01	2016-01-05	Oxford Biotherapeutics Ltd.	Anti-ROR1 antibodies and methods of use for treatment of cancer
UA112062C2 (uk) †	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
JP5974012B2 (ja)	2010-10-05	2016-08-23	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
EA201390669A1 (ru)	2010-11-10	2013-11-29	Дженентек, Инк.	Способы и композиции для иммунотерапии заболеваний нервной системы
EP2637692A4 (de)	2010-11-12	2014-09-10	Scott & White Healthcare	Antikörper gegen den endothelialen tumormarker 8
KR101615420B1 (ko)	2010-12-16	2016-04-26	제넨테크, 인크.	Th2 억제에 관한 진단 및 치료
MA34881B1 (fr)	2010-12-20	2014-02-01	Genentech Inc	Anticorps et immunoconjugués anti-mésothéline
JP2014511106A (ja)	2010-12-22	2014-05-08	ジェネンテック，インコーポレイテッド	抗ｐｃｓｋ９抗体及び使用方法
EP2655413B1 (de)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
AR085138A1 (es)	2011-02-04	2013-09-11	Genentech Inc	VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US20140088019A1 (en)	2011-02-11	2014-03-27	Zyngenia, Inc.	Monovalent and Multivalent Multispecific Complexes and Uses Thereof
CN103687619A (zh)	2011-02-14	2014-03-26	特罗科隆科学有限公司	用于对流行性感冒进行治疗以及诊断的组合物以及方法
RU2013144392A (ru)	2011-03-03	2015-04-10	Апексиджен, Инк.	Антитела к рецептору il-6 и способы применения
US8609818B2 (en)	2011-03-10	2013-12-17	Omeros Corporation	Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CN103533929A (zh)	2011-03-15	2014-01-22	特罗科隆科学有限公司	用于流行性感冒的治疗和诊断的组合物和方法
CN103561771B (zh)	2011-03-17	2019-01-04	伯明翰大学	重新定向的免疫治疗
HUE041335T2 (hu)	2011-03-29	2019-05-28	Roche Glycart Ag	Antitest FC-variánsok
JP2014516511A (ja)	2011-04-07	2014-07-17	ジェネンテック，インコーポレイテッド	抗ｆｇｆｒ４抗体及び使用方法
RU2013150331A (ru)	2011-04-20	2015-05-27	Рош Гликарт Аг	СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
CN106928362B (zh)	2011-04-29	2021-10-26	埃派斯进有限公司	抗-cd40抗体及其使用方法
TWI547500B (zh)	2011-05-16	2016-09-01	建南德克公司	Ｆｇｆｒ１促效劑及其使用方法
ES2704038T3 (es)	2011-05-24	2019-03-13	Zyngenia Inc	Complejos multiespecíficos multivalentes y monovalentes y sus usos
FI3415531T3 (fi)	2011-05-27	2023-09-07	Glaxo Group Ltd	Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
TWI603741B (zh)	2011-06-10	2017-11-01	梅爾莎納醫療公司	蛋白質-聚合物-藥物共軛體
WO2013003507A1 (en)	2011-06-27	2013-01-03	Morphotek, Inc.	Multifunctional agents
US20130004484A1 (en)	2011-06-30	2013-01-03	Genentech, Inc.	Anti-c-met antibody formulations
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
EP2742067A4 (de)	2011-08-12	2015-03-04	Omeros Corp	Monoklonale fzd10-antikörper und verfahren zu ihrer verwendung
US20140363438A1 (en)	2011-08-17	2014-12-11	Genentech, Inc.	Neuregulin antibodies and uses thereof
MX2014001736A (es)	2011-08-17	2014-03-31	Genentech Inc	Inhibicion de angiogenesis en tumores refractarios.
KR101886983B1 (ko)	2011-08-23	2018-08-08	로슈 글리카트 아게	2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
BR112014004168A2 (pt)	2011-08-23	2017-12-12	Roche Glycart Ag	anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
US8822651B2 (en)	2011-08-30	2014-09-02	Theraclone Sciences, Inc.	Human rhinovirus (HRV) antibodies
BR112014005720A2 (pt)	2011-09-15	2017-12-12	Genentech Inc	método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
AR087918A1 (es)	2011-09-19	2014-04-23	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
MX2014002996A (es)	2011-09-23	2014-05-28	Roche Glycart Ag	Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
US20130089562A1 (en)	2011-10-05	2013-04-11	Genenthech, Inc.	Methods of treating liver conditions using notch2 antagonists
DK2766392T3 (da)	2011-10-10	2019-10-07	Xencor Inc	Fremgangsmåde til oprensning af antistoffer
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
SI2766393T1 (sl)	2011-10-14	2018-10-30	F. Hoffmann-La Roche Ag	Protitelesa Anti-HtrA1 in postopki uporabe
MX355128B (es)	2011-10-14	2018-04-06	Genentech Inc	Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
CN104040341B (zh)	2011-10-25	2016-12-28	斯隆－凯特林纪念癌症中心	用于前列腺癌的诊断、预测和治疗的游离psa抗体
EP2776051A4 (de)	2011-10-28	2015-06-17	Hoffmann La Roche	Therapeutische kombinationen und verfahren zur behandlung von melanomen
RU2014122184A (ru)	2011-11-02	2015-12-10	Апексиджен, Инк.	Антитела к kdr и способы их применения
EP2589609A1 (de)	2011-11-03	2013-05-08	Pierre Fabre Medicament	Antigenbindendes Protein und dessen Verwendung als Adressierungsprodukt bei der Behandlung von Krebs
HK1200842A1 (en)	2011-11-18	2015-08-14	Albumedix Ltd	Proteins with improved half-life and other properties
CN104066748A (zh)	2011-11-21	2014-09-24	霍夫曼-拉罗奇有限公司	抗c-met抗体的纯化
AU2012372140B9 (en)	2011-12-08	2015-10-15	Biotest Ag	Uses of immunoconjugates targeting CD138
EP2791174B1 (de)	2011-12-15	2018-02-28	F. Hoffmann-La Roche AG	Antikörper gegen menschlichen csf-1r und deren verwendungen
WO2013096812A1 (en)	2011-12-23	2013-06-27	Genentech, Inc.	Articles of manufacture and methods for co-administration of antibodies
US20150011431A1 (en)	2012-01-09	2015-01-08	The Scripps Research Institute	Humanized antibodies
EP2802603A4 (de)	2012-01-09	2015-11-04	Scripps Research Inst	Ultralange komplementaritätsbestimmungsbereiche und verwendungen davon
JP2015506944A (ja)	2012-01-18	2015-03-05	ジェネンテック，インコーポレイテッド	Ｆｇｆ１９修飾薬を使用する方法
PE20141561A1 (es)	2012-01-18	2014-11-12	Genentech Inc	Anticuerpos anti-lrp5 y metodos de uso
WO2013116686A1 (en)	2012-02-02	2013-08-08	Massachusetts Institute Of Technology	Methods and products related to targeted cancer therapy
CN104105711B (zh)	2012-02-10	2018-11-30	弗·哈夫曼-拉罗切有限公司	单链抗体及其他异多聚体
SG11201404703WA (en)	2012-02-11	2014-09-26	Genentech Inc	R-spondin translocations and methods using the same
ES2676031T3 (es)	2012-02-15	2018-07-16	F. Hoffmann-La Roche Ag	Cromatografía de afinidad basada en el receptor Fc
GB201203442D0 (en)	2012-02-28	2012-04-11	Univ Birmingham	Immunotherapeutic molecules and uses
CN104736559B (zh)	2012-03-16	2022-04-08	阿尔布梅迪克斯医疗有限公司	白蛋白变体
WO2013148259A1 (en)	2012-03-28	2013-10-03	Massachusetts Institute Of Technology	Cancer-related extracellular matrix signatures and related methods and products
US10024860B2 (en)	2012-03-28	2018-07-17	Massachusetts Institute Of Technology	Cancer-related extracellular matrix signatures and related methods and products
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AR090903A1 (es)	2012-05-01	2014-12-17	Genentech Inc	Anticuerpos e inmunoconjugados anti-pmel17
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
CA2875096A1 (en)	2012-06-15	2013-12-19	Genentech, Inc.	Anti-pcsk9 antibodies, formulations, dosing, and methods of use
HK1207864A1 (zh)	2012-06-27	2016-02-12	F. Hoffmann-La Roche Ag	用於选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
MX2014014065A (es)	2012-06-27	2015-02-04	Hoffmann La Roche	Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
MX2014014804A (es)	2012-06-27	2015-02-12	Hoffmann La Roche	Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
BR112014030844A2 (pt)	2012-07-04	2019-10-15	Hoffmann La Roche	anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
MX353951B (es)	2012-07-04	2018-02-07	Hoffmann La Roche	Anticuerpos de anti-teofilina y metodos de uso.
WO2014006124A1 (en)	2012-07-04	2014-01-09	F. Hoffmann-La Roche Ag	Covalently linked antigen-antibody conjugates
WO2014009465A1 (en)	2012-07-13	2014-01-16	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013306098A1 (en)	2012-08-18	2015-02-12	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
UA118251C2 (uk)	2012-08-23	2018-12-26	Ейдженсіс, Інк.	Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 158p1d7
EP3211006A3 (de)	2012-09-19	2017-11-08	AbbVie Biotherapeutics Inc.	Varianten tnf alpha antikorper
WO2014056783A1 (en)	2012-10-08	2014-04-17	Roche Glycart Ag	Fc-free antibodies comprising two fab-fragments and methods of use
RS60000B1 (sr)	2012-10-11	2020-04-30	Daiichi Sankyo Co Ltd	Veznici za antitelo-lek konjugate
EP2910573B1 (de)	2012-10-19	2020-02-19	Daiichi Sankyo Company, Limited	Durch bindung über einen linker mit hydrophiler struktur hergestelltes antikörper-wirkstoff-konjugat
CA2889756C (en)	2012-10-26	2023-03-14	Memorial Sloan-Kettering Cancer Center	Thiohydantoin compounds as androgen receptor modulators
CA2888763A1 (en)	2012-10-30	2014-05-08	Apexigen, Inc.	Anti-cd40 antibodies and methods of use
ES2937015T3 (es)	2012-11-01	2023-03-23	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Anticuerpo contra CD269 (BCMA)
TWI609887B (zh)	2012-11-05	2018-01-01	皮爾法伯製藥公司	新穎的抗原結合蛋白及其作爲治療癌症之定址產物的用途
CN105452290A (zh)	2012-11-08	2016-03-30	诺维信生物制药丹麦公司	白蛋白变体
AU2013343667A1 (en)	2012-11-08	2015-04-02	F. Hoffmann-La Roche Ag	HER3 antigen binding proteins binding to the beta-hairpin of HER3
US9284365B2 (en)	2012-11-13	2016-03-15	Genentech, Inc.	Anti-hemagglutinin antibodies and methods of use
CN105849086B (zh)	2012-11-24	2018-07-31	杭州多禧生物科技有限公司	亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
WO2014093394A1 (en)	2012-12-10	2014-06-19	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
EP2931316B1 (de)	2012-12-12	2019-02-20	Mersana Therapeutics, Inc.	Hydroxylpolymer-heilmittelproteinkonjugate
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
LT2943511T (lt)	2013-01-14	2019-11-11	Xencor Inc	Nauji heterodimeriniai baltymai
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
EP2945969A1 (de)	2013-01-15	2015-11-25	Xencor, Inc.	Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
HK1211235A1 (en)	2013-02-22	2016-05-20	霍夫曼-拉罗奇有限公司	Methods of treating cancer and preventing drug resistance
EP2961772A1 (de)	2013-02-26	2016-01-06	Roche Glycart AG	Anti-mcsp-antikörper
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
HK1220916A1 (zh)	2013-03-14	2017-05-19	基因泰克公司	治疗癌症和预防癌症药物抗性的方法
EA201591750A1 (ru)	2013-03-14	2016-05-31	Дженентек, Инк.	Антитела против b7-h4 и иммуноконъюгаты
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
RU2015144033A (ru)	2013-03-15	2017-04-26	Эббви Байотекнолоджи Лтд.	Антитела против cd25 и их применения
EP3936521B1 (de)	2013-03-15	2026-02-11	Xencor, Inc.	Heterodimere proteine
HK1220470A1 (zh)	2013-03-15	2017-05-05	Abbvie Biotechnology Ltd.	抗cd25抗体及其用途
MX374811B (es)	2013-03-15	2025-03-06	Ac Immune Sa	Anticuerpos anti-tau y métodos de uso.
EP2968537A1 (de)	2013-03-15	2016-01-20	Genentech, Inc.	Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
PL2972373T3 (pl)	2013-03-15	2020-03-31	F. Hoffmann-La Roche Ag	Biomarkery i sposoby leczenia stanów związanych z PD-1 i PD-L1
WO2014144600A2 (en)	2013-03-15	2014-09-18	Viktor Roschke	Multivalent and monovalent multispecific complexes and their uses
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
US10544187B2 (en)	2013-03-15	2020-01-28	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
KR20150131177A (ko)	2013-03-15	2015-11-24	제넨테크, 인크.	항-CRTh2 항체 및 그의 용도
MA38495A1 (fr)	2013-03-15	2017-08-31	Genentech Inc	Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
MX368665B (es)	2013-03-15	2019-10-10	Abbvie Biotherapeutics Inc	Variantes de fc.
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
US20160068613A1 (en)	2013-04-29	2016-03-10	Hoffmann-La Roche Inc.	Fc-receptor binding modified asymmetric antibodies and methods of use
WO2014179657A1 (en)	2013-05-03	2014-11-06	Eleven Biotherapeutics, Inc.	Albumin variants binding to fcrn
EP4324480A3 (de)	2013-05-20	2024-05-08	F. Hoffmann-La Roche AG	Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
WO2014210397A1 (en)	2013-06-26	2014-12-31	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (de)	2013-06-27	2019-12-11	Academia Sinica	Glykankonjugate und verwendung davon
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CN111518199A (zh)	2013-07-18	2020-08-11	图鲁斯生物科学有限责任公司	具有超长互补决定区的人源化抗体
EP3027220A1 (de)	2013-08-01	2016-06-08	Agensys, Inc.	An cd37-proteine bindende antikörper-wirkstoffkonjugate (adc)
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP3041484B1 (de)	2013-09-06	2021-03-03	Academia Sinica	Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
RU2016109247A (ru)	2013-09-17	2017-10-19	Дженентек, Инк.	Способы применения антител к lgr5
EP3054973B1 (de)	2013-10-10	2020-12-02	Beth Israel Deaconess Medical Center, Inc.	Tm4sf1-bindende proteine und verfahren zur verwendung davon
CU24320B1 (es)	2013-10-11	2018-02-08	Berlin Chemie Ag	Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
KR102355745B1 (ko)	2013-10-11	2022-01-26	아사나 바이오사이언시스 엘엘씨	단백질-폴리머-약물 접합체
ES2726850T3 (es)	2013-10-11	2019-10-09	Mersana Therapeutics Inc	Conjugados de proteína-polímero-fármaco
TWI658052B (zh)	2013-10-18	2019-05-01	美商建南德克公司	抗－ｒｓｐｏ抗體及使用方法
CA2929283C (en) *	2013-11-04	2022-07-19	Pfizer Inc.	Intermediates and methods for synthesizing calicheamicin derivatives
EP3065780A1 (de) *	2013-11-04	2016-09-14	Pfizer Inc.	Anti-efna4-antikörper-arzneimittelkonjugate
AR098743A1 (es)	2013-12-13	2016-06-08	Genentech Inc	Anticuerpos e inmunoconjugados anti-cd33
SG11201604905WA (en)	2013-12-16	2016-07-28	Genentech Inc	Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015100113A2 (en)	2013-12-23	2015-07-02	Memorial Sloan-Kettering Cancer Center	Methods and compositions for treating cancer using peptide nucleic acid-based agents
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
MX373097B (es)	2014-01-03	2020-04-27	Hoffmann La Roche	Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
CA2930154A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CN105873616B (zh)	2014-01-03	2020-06-05	豪夫迈·罗氏有限公司	共价连接的多肽毒素-抗体缀合物
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10023892B2 (en)	2014-05-27	2018-07-17	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015112909A1 (en)	2014-01-24	2015-07-30	Genentech, Inc.	Methods of using anti-steap1 antibodies and immunoconjugates
MX2016009332A (es)	2014-01-29	2016-12-20	Shanghai hengrui pharmaceutical co ltd	Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo.
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
CN111499741A (zh)	2014-02-12	2020-08-07	豪夫迈·罗氏有限公司	抗锯齿蛋白1抗体及使用方法
PE20161171A1 (es)	2014-02-21	2016-11-08	Genentech Inc	Anticuerpos bioespecificos anti-il-13/il-17 y sus usos referencia cruzada a solicitudes relacionadas
DK3122757T3 (da)	2014-02-28	2023-10-09	Hangzhou Dac Biotech Co Ltd	Ladede linkere og anvendelse deraf til konjugering
MX2016011637A (es)	2014-03-14	2017-04-13	Genentech Inc	Metodos y composiciones para secrecion de polipeptidos heterologos.
JP6744855B2 (ja)	2014-03-21	2020-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗体のｉｎｖｉｖｏでの半減期のｉｎｖｉｔｒｏでの予測
TW202330606A (zh)	2014-03-21	2023-08-01	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015148915A1 (en)	2014-03-27	2015-10-01	Academia Sinica	Reactive labelling compounds and uses thereof
AU2015237184B2 (en)	2014-03-28	2020-11-26	Xencor, Inc.	Bispecific antibodies that bind to CD38 and CD3
HUE046767T2 (hu)	2014-03-31	2020-03-30	Hoffmann La Roche	Anti-OX40 antitestek és alkalmazási eljárások
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
SG11201608192SA (en)	2014-04-11	2016-10-28	Medimmune Llc	Bispecific her2 antibodies
BR112016024575B1 (pt)	2014-04-25	2024-02-27	Pierre Fabre Medicament	Anticorpo monoclonal de internalização, ou um fragmento de ligação a igf-1r de internalização do mesmo, seus usos, hibridoma murino, conjugado anticorpo-fármaco, e composição farmacêutica e seus usos
BR112016025291A2 (pt)	2014-04-30	2017-12-26	Abbvie Stemcentrx Llc	conjugados de anticorpo anti-ptk7-fármaco
BR112016024462B1 (pt)	2014-05-06	2022-12-27	Genentech, Inc	Métodos para a preparação de um anticorpo
RU2016150370A (ru)	2014-05-22	2018-06-26	Дженентек, Инк.	Антитела и иммуноконъюгаты против GPC3
BR112016025040A2 (en)	2014-05-23	2018-02-20	Genentech, Inc.	methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
JP7062361B2 (ja)	2014-05-27	2022-05-06	アカデミアシニカ	抗ｈｅｒ２糖操作抗体群およびその使用
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US20150344585A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
CN106714829A (zh)	2014-05-28	2017-05-24	中央研究院	抗TNF‑α醣抗体及其用途
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
EP3164419B1 (de)	2014-06-26	2024-07-24	F. Hoffmann-La Roche AG	Anti-brdu-antikörper und verfahren zur verwendung
EP3166627A1 (de)	2014-07-11	2017-05-17	Genentech, Inc.	Notch-signalweghemmung
US20160060360A1 (en)	2014-07-24	2016-03-03	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
ES3034398T3 (en)	2014-08-28	2025-08-18	Bioatla Inc	Conditionally active chimeric antigen receptors for modified t-cells
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
EP3191518B1 (de)	2014-09-12	2020-01-15	Genentech, Inc.	Anti-b7-h4-antikörper und immunkonjugate
CA2957354A1 (en)	2014-09-12	2016-03-17	Genentech, Inc.	Cysteine engineered antibodies and conjugates
TWI758784B (zh)	2014-09-12	2022-03-21	美商建南德克公司	抗her2抗體及免疫結合物
SG11201701627PA (en)	2014-09-12	2017-03-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
WO2016049214A1 (en)	2014-09-23	2016-03-31	Genentech, Inc.	METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
AU2015324924B2 (en)	2014-10-01	2021-07-01	Medimmune, Llc	Method of conjugating a polypeptide
WO2016061389A2 (en)	2014-10-16	2016-04-21	Genentech, Inc.	Anti-alpha-synuclein antibodies and methods of use
JP6723509B2 (ja)	2014-10-24	2020-07-15	日油株式会社	環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
CN107148283A (zh)	2014-10-31	2017-09-08	豪夫迈·罗氏有限公司	抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
US20160160290A1 (en)	2014-11-03	2016-06-09	Genentech, Inc.	Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CN106796235B (zh)	2014-11-03	2021-01-29	豪夫迈·罗氏有限公司	用于检测t细胞免疫子集的测定法及其使用方法
CA2961439A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
DK3215528T3 (da)	2014-11-06	2019-10-07	Hoffmann La Roche	Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
TWI705976B (zh)	2014-11-10	2020-10-01	美商建南德克公司	抗介白素-33抗體及其用途
EP3221364B1 (de)	2014-11-19	2020-12-16	Genentech, Inc.	Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
CN107001473B (zh)	2014-11-19	2021-07-09	豪夫迈·罗氏有限公司	抗-运铁蛋白受体抗体及使用方法
US11008403B2 (en)	2014-11-19	2021-05-18	Genentech, Inc.	Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
MA41019A (fr)	2014-11-26	2021-05-05	Xencor Inc	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
KR102689285B1 (ko)	2014-11-26	2024-07-31	젠코어 인코포레이티드	Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
ES2764111T3 (es)	2014-12-03	2020-06-02	Hoffmann La Roche	Anticuerpos multiespecíficos
AR102918A1 (es)	2014-12-05	2017-04-05	Genentech Inc	Anticuerpos anti-cd79b y métodos de uso
CN107207591A (zh)	2014-12-10	2017-09-26	豪夫迈·罗氏有限公司	血脑屏障受体抗体及使用方法
JP6862343B2 (ja)	2014-12-19	2021-04-21	アブリンクスエン．ヴェー．	システイン結合ナノボディダイマー
WO2016098356A1 (en)	2014-12-19	2016-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-c5 antibodies and methods of use
KR102650420B1 (ko)	2014-12-19	2024-03-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US10428155B2 (en)	2014-12-22	2019-10-01	Xencor, Inc.	Trispecific antibodies
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US20160208018A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
GB201501004D0 (en)	2015-01-21	2015-03-04	Cancer Rec Tech Ltd	Inhibitors
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
WO2016118191A1 (en)	2015-01-24	2016-07-28	Academia Sinica	Novel glycan conjugates and methods of use thereof
WO2016118961A1 (en)	2015-01-24	2016-07-28	Academia Sinica	Cancer markers and methods of use thereof
CA2971288A1 (en)	2015-02-02	2016-08-11	The University Of Birmingham	Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
HK1244512A1 (zh)	2015-02-04	2018-08-10	健泰科生物技术公司	突变型smoothened及其使用方法
CN112142844B (zh)	2015-02-05	2025-07-25	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
AU2016250537A1 (en) *	2015-04-21	2018-11-08	Abbvie Stemcentrx Llc	Calicheamicin constructs and methods of use
CA2980189A1 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
PL3286315T3 (pl)	2015-04-24	2021-11-02	F. Hoffmann-La Roche Ag	Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
EP3778640A1 (de)	2015-05-01	2021-02-17	Genentech, Inc.	Maskierte anti-cd3-antikörper und verfahren zur verwendung
CN116196414A (zh)	2015-05-11	2023-06-02	豪夫迈·罗氏有限公司	治疗狼疮性肾炎的组合物和方法
JP7048319B2 (ja)	2015-05-12	2022-04-05	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
PL3303632T5 (pl)	2015-05-29	2023-07-03	F. Hoffmann-La Roche Ag	Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
CA2985483A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies
WO2016200835A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA2986928A1 (en)	2015-06-16	2016-12-22	Genentech, Inc.	Humanized and affinity matured antibodies to fcrh5 and methods of use
EP3310378B1 (de)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anti-cll-1-antikörper und verfahren zur verwendung
JP2018526972A (ja)	2015-06-16	2018-09-20	ジェネンテック，インコーポレイテッド	抗ｃｄ３抗体及び使用方法
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
JP7021955B2 (ja)	2015-06-24	2022-03-03	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
JP6691144B2 (ja)	2015-06-24	2020-04-28	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	目的に合わせた親和性を有する抗トランスフェリンレセプター抗体
CN108473573A (zh)	2015-06-29	2018-08-31	豪夫迈·罗氏有限公司	Ii型抗cd20抗体用于器官移植中
FI3319936T3 (fi)	2015-07-12	2026-03-12	Hangzhou Dac Biotech Co Ltd	Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
PH12018500203B1 (en)	2015-08-05	2023-02-22	Janssen Biotech Inc	Anti-cd154 antibodies and methods of using them
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
MX2018001825A (es)	2015-08-20	2018-05-07	Albumedix As	Variantes y conjugados de albumina.
EP3350224B1 (de)	2015-09-20	2024-06-19	The United States of America, as Represented By the Secretary, Department of Health and Human Services	Für fibroblastenwachstumsfaktor-rezeptor 4 (fgfr4) spezifische monoklonale antikörper und verfahren zu deren verwendung
UA125432C2 (uk)	2015-09-23	2022-03-09	Дженентек, Інк.	Оптимізовані варіанти анти-vegf антитіл
EP3352791B1 (de)	2015-09-24	2019-10-30	AbVitro LLC	Hiv-antikörperzusammensetzungen und verfahren zur verwendung
CN113912724B (zh)	2015-09-25	2025-03-14	豪夫迈·罗氏有限公司	抗tigit抗体和使用方法
KR102770238B1 (ko)	2015-09-30	2025-02-18	얀센 바이오테크 인코포레이티드	인간 cd40에 특이적으로 결합하는 작용성 항체 및 사용 방법
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MY192202A (en)	2015-10-02	2022-08-06	Hoffmann La Roche	Bispecific antibodies specific for pd1 and tim3
EP3356406A1 (de)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispezifische antikörper gegen menschliches cd20/gegen den menschlichen transferrinrezeptor und verfahren zur verwendung
RS62450B1 (sr)	2015-10-02	2021-11-30	Hoffmann La Roche	Anti-pd1 antitela i postupci primene
JP6621919B2 (ja)	2015-10-16	2019-12-18	ジェネンテック，インコーポレイテッド	束縛ジスルフィド薬物コンジュゲート
JP6852065B2 (ja)	2015-10-20	2021-03-31	ジェネンテック，インコーポレイテッド	カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
EP3184547A1 (de)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg-antikörper und verfahren zur verwendung
ES2904553T3 (es)	2015-10-30	2022-04-05	Hoffmann La Roche	Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
HUE057837T2 (hu)	2015-11-03	2022-06-28	Janssen Biotech Inc	PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
CN108602884B (zh)	2015-11-08	2024-06-25	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
ES2873846T5 (en)	2015-11-19	2025-06-23	Revitope Ltd	Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
PT3383920T (pt)	2015-11-30	2024-04-15	Univ California	Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
WO2017100372A1 (en)	2015-12-07	2017-06-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and psma
IL313608A (en)	2015-12-09	2024-08-01	Hoffmann La Roche	Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3178848A1 (de)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
RU2742606C2 (ru)	2015-12-18	2021-02-09	Чугаи Сейяку Кабусики Кайся	Антитела к с5 и способы их применения
CA3002422C (en)	2015-12-18	2024-04-16	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN108495653A (zh)	2016-01-27	2018-09-04	免疫医疗有限责任公司	用于制备具有定义的糖基化模式抗体的方法
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
FI3895736T3 (fi)	2016-02-05	2023-06-26	Rigshospitalet	Uparap:hen kohdistuvia vasta-aine-lääkekonjugaatteja
CN114395624A (zh)	2016-02-29	2022-04-26	基因泰克公司	用于癌症的治疗和诊断方法
EP3427055A1 (de)	2016-03-07	2019-01-16	Pierre Fabre Medicament	Neues universelles verfahren zur aufnahme und analyse von adcs zur charakterisierung der wirkstoffverteilung und des wirkstoff-antikörper-verhältnisses bei biologischen proben
WO2017156192A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
WO2017172907A1 (en) *	2016-03-29	2017-10-05	Sorrento Therapeutics, Inc.	Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
CA3056374A1 (en)	2016-04-13	2017-10-19	Orimabs Ltd.	Anti-psma antibodies and use thereof
EP3443004A1 (de)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Anti-rspo3-antikörper und verfahren zur verwendung
PE20190353A1 (es)	2016-04-15	2019-03-07	Macrogenics Inc	Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
KR20190003958A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암의 치료 및 모니터링 방법
AU2017248644B2 (en)	2016-04-15	2019-10-31	Bioatla, Llc	Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
CN109154027A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
EP3889175A1 (de)	2016-05-02	2021-10-06	F. Hoffmann-La Roche AG	Der contorsbody - ein einkettiger targetbinder
WO2017196847A1 (en)	2016-05-10	2017-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
LT3455261T (lt)	2016-05-13	2022-11-10	Bioatla, Inc.	Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas
CN109313200B (zh)	2016-05-27	2022-10-04	豪夫迈·罗氏有限公司	用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017207540A1 (en)	2016-05-30	2017-12-07	Toxinvent Oü	Antibody-drug-conjugates comprising novel anthracycline-derivatives for cancer treatment
EP3252078A1 (de)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
CA3059010A1 (en)	2016-06-02	2018-12-06	F. Hoffmann-La Roche Ag	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2017214182A1 (en)	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
BR112018075644A2 (pt)	2016-06-08	2019-04-09	Abbvie Inc.	anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015274A (es)	2016-06-08	2019-10-07	Abbvie Inc	Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PL3458479T4 (pl)	2016-06-08	2021-07-26	Abbvie Inc.	Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
ES2963807T3 (es)	2016-06-08	2024-04-02	Xencor Inc	Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
CN109563167A (zh)	2016-06-08	2019-04-02	艾伯维公司	抗b7-h3抗体和抗体药物偶联物
KR102838691B1 (ko)	2016-06-14	2025-07-25	젠코어 인코포레이티드	이중특이적 체크포인트 억제제 항체
KR102680483B1 (ko)	2016-06-17	2024-07-01	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
WO2018004338A1 (en)	2016-06-27	2018-01-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
CN116063545A (zh)	2016-06-28	2023-05-05	Xencor股份有限公司	结合生长抑素受体2的异源二聚抗体
JP2019524706A (ja)	2016-07-08	2019-09-05	ジェネンテック，インコーポレイテッド	Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
KR20230107408A (ko)	2016-07-29	2023-07-14	주노 쎄러퓨티크스 인코퍼레이티드	항-cd19 항체에 대한 항-이디오타입 항체
CA3031559A1 (en)	2016-08-02	2018-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
EP3493853A1 (de)	2016-08-03	2019-06-12	Pfizer Inc	Heteroarylsulfonbasierte konjugationsgriffe, verfahren zu deren herstellung und deren verwendung zur synthese von antikörperarzneimittelkonjugaten
WO2018027204A1 (en)	2016-08-05	2018-02-08	Genentech, Inc.	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
MX2019001448A (es)	2016-08-05	2019-09-13	Chugai Pharmaceutical Co Ltd	Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
RS64925B1 (sr)	2016-08-10	2023-12-29	Legend Biotech Ireland Ltd	Himerni antigenski receptori koji ciljaju bcma i postupci njihove upotrebe
TWI764917B (zh)	2016-08-22	2022-05-21	醣基生醫股份有限公司	抗體、結合片段及使用方法
EP3504239B1 (de)	2016-08-25	2024-05-29	F. Hoffmann-La Roche AG	Intervalldosierung eines anti-csf-1r-antikörpers in kombination mit makrophagenaktivierungsmittel
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh)	2016-09-19	2022-11-29	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
US10550185B2 (en)	2016-10-14	2020-02-04	Xencor, Inc.	Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
CN118359705A (zh)	2016-10-19	2024-07-19	英温拉公司	抗体构建体
US11555076B2 (en)	2016-10-29	2023-01-17	Genentech, Inc.	Anti-MIC antibodies and methods of use
KR20220147721A (ko)	2016-11-14	2022-11-03	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
MX2019005438A (es)	2016-11-15	2019-08-16	Genentech Inc	Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
CA3036983A1 (en)	2016-11-21	2018-05-24	Cureab Gmbh	Anti-gp73 antibodies and immunoconjugates
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
US11236171B2 (en)	2016-12-21	2022-02-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies specific for FLT3 and uses thereof
MX2019007019A (es)	2016-12-22	2019-08-16	Univ Degli Studi Magna Graecia Catanzaro	Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
JP7304287B2 (ja)	2016-12-22	2023-07-06	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
CA3051038C (en) *	2017-01-24	2022-07-26	Pfizer Inc.	Calicheamicin derivatives and antibody drug conjugates thereof
MY197534A (en)	2017-02-10	2023-06-21	Genentech Inc	Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010295A (es)	2017-03-01	2019-11-21	Genentech Inc	Métodos de diagnóstico y terapéuticos para el cáncer.
KR102769634B1 (ko)	2017-04-27	2025-02-19	테사로, 인코포레이티드	림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
EP3625256A1 (de)	2017-05-19	2020-03-25	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
TW201905037A (zh)	2017-06-22	2019-02-01	美商梅爾莎納醫療公司	藥物攜帶聚合物支架及蛋白質聚合物藥物共軛物之製造方法
WO2019005208A1 (en)	2017-06-30	2019-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en)	2017-06-30	2019-01-03	Lentigen Technology, Inc.	Human monoclonal antibodies specific for cd33 and methods of their use
JP2020529832A (ja)	2017-06-30	2020-10-15	ゼンコアインコーポレイテッド	ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
US20190048073A1 (en)	2017-07-20	2019-02-14	Pfizer Inc.	Anti-gd3 antibodies and antibody-drug conjugates
AU2018304458B2 (en)	2017-07-21	2021-12-09	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
WO2019078357A1 (ja)	2017-10-20	2019-04-25	中外製薬株式会社	細胞への分子の取り込みを測定する方法
JP2021500391A (ja)	2017-10-24	2021-01-07	マジェンタセラピューティクスインコーポレイテッドＭａｇｅｎｔａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｃｄ１１７＋細胞を減少させるための組成物及び方法
MX2020004100A (es)	2017-10-30	2020-07-24	Hoffmann La Roche	Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
CN111295392A (zh)	2017-11-01	2020-06-16	豪夫迈·罗氏有限公司	Compbody–多价靶结合物
SG11202003501XA (en)	2017-11-01	2020-05-28	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
PL3704146T3 (pl)	2017-11-01	2022-03-07	F. Hoffmann-La Roche Ag	Przeciwciało Contorsbody trifab
JP7544597B2 (ja)	2017-11-06	2024-09-03	ジェネンテック，インコーポレイテッド	がんの診断及び療法
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en)	2017-11-08	2022-04-26	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3710589A4 (de)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s-antikörper und verfahren zur verwendung
CN119857155A (zh)	2017-11-29	2025-04-22	海德堡医药研究有限责任公司	用于耗尽cd5+细胞的组合物和方法
IL275426B2 (en)	2017-12-19	2025-03-01	Xencor Inc	Engineered il-2 fc fusion proteins
TWI817974B (zh)	2017-12-28	2023-10-11	日商中外製藥股份有限公司	細胞毒性誘導治療劑
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3740505A1 (de)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
PE20211116A1 (es)	2018-02-08	2021-06-23	Genentech Inc	Moleculas biespecificas de union al antigeno y metodos de uso
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
KR20200131867A (ko)	2018-03-14	2020-11-24	더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈	항-cd33 키메라 항원 수용체 및 이의 용도
CN116327926A (zh)	2018-03-15	2023-06-27	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
EP3773911A2 (de)	2018-04-04	2021-02-17	Xencor, Inc.	Heterodimere antikörper, die das fibroblastenaktivierungsprotein binden
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
US11505595B2 (en)	2018-04-18	2022-11-22	Xencor, Inc.	TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2019204665A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US20210299286A1 (en)	2018-05-04	2021-09-30	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
WO2019212357A1 (en)	2018-05-04	2019-11-07	Tagworks Pharmaceuticals B.V.	Compounds comprising a linker for increasing transcyclooctene stability
CA3100005A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
EP3794024B1 (de)	2018-05-14	2023-05-10	Werewolf Therapeutics, Inc.	Aktivierbare interleukin-2-polypeptide und verfahren zu ihrer verwendung
CN112513085B (zh)	2018-05-24	2024-06-18	詹森生物科技公司	Psma结合剂及其用途
IL322895A (en)	2018-06-05	2025-10-01	King S College London	Btnl3/8-targeted constructs for delivery of cargo to the digestive system
CR20210047A (es)	2018-07-02	2021-05-21	Amgen Inc	Proteína de unión al antígeno anti-steap1
JP7554742B2 (ja)	2018-07-03	2024-09-20	マレンゴ・セラピューティクス，インコーポレーテッド	抗ｔｃｒ抗体分子およびその使用
WO2020014482A1 (en)	2018-07-12	2020-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Affinity matured cd22-specific monoclonal antibody and uses thereof
WO2020023561A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
US12012463B2 (en)	2018-08-08	2024-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-2 and uses thereof
PE20210343A1 (es)	2018-08-10	2021-02-23	Chugai Pharmaceutical Co Ltd	Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
WO2020052542A1 (en)	2018-09-10	2020-03-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against cll1 and constructs thereof
EP4268831A3 (de)	2018-09-12	2024-05-22	Fred Hutchinson Cancer Center	Verminderung der cd33-expression zum selektiven schutz von therapeutischen zellen
KR20210063330A (ko)	2018-09-19	2021-06-01	제넨테크, 인크.	방광암에 대한 치료 및 진단 방법
WO2020063676A1 (zh)	2018-09-26	2020-04-02	江苏恒瑞医药股份有限公司	依喜替康类似物的配体-药物偶联物及其制备方法和应用
CA3112989A1 (en)	2018-09-27	2020-04-02	Xilio Development, Inc.	Masked cytokine polypeptides
JP7612571B2 (ja)	2018-10-03	2025-01-14	ゼンコアインコーポレイテッド	Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
MA54052A (fr)	2018-10-29	2022-02-09	Hoffmann La Roche	Formulation d'anticorps
EP3873534A1 (de)	2018-10-29	2021-09-08	Mersana Therapeutics, Inc.	Cystein-modifizierte antikörper-wirkstoff-konjugate mit peptidhaltigen linkern
JP7553440B2 (ja)	2018-11-07	2024-09-18	クリスパーセラピューティクスアクチェンゲゼルシャフト	抗ｃｄ３３免疫細胞癌療法
WO2020106886A1 (en)	2018-11-20	2020-05-28	Cornell University	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
MX2021006573A (es)	2018-12-06	2021-07-15	Genentech Inc	Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
JP2022514290A (ja)	2018-12-20	2022-02-10	ジェネンテック，インコーポレイテッド	改変抗体ｆｃおよび使用方法
WO2020127968A1 (en)	2018-12-20	2020-06-25	Marino Stephen F	Protein-drug conjugate comprising a monomeric form of proteinase 3
SG11202106498XA (en)	2018-12-26	2021-07-29	Xilio Development Inc	Anti-ctla4 antibodies and methods of use thereof
EP3883608A1 (de)	2019-01-08	2021-09-29	The United States of America, as represented by the Secretary, Department of Health and Human Services	Speziesübergreifende einzeldomänenantikörper gegen mesothelin zur behandlung von soliden tumoren
CA3126359A1 (en)	2019-01-22	2020-07-30	Genentech, Inc.	Immunoglobulin a antibodies and methods of production and use
US12122843B2 (en)	2019-01-22	2024-10-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
JPWO2020153467A1 (ja)	2019-01-24	2021-12-02	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
AU2020215576A1 (en)	2019-01-29	2021-07-08	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
CN113710706A (zh)	2019-02-27	2021-11-26	豪夫迈·罗氏有限公司	用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
BR112021016955A2 (pt)	2019-03-01	2021-11-23	Xencor Inc	Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
MY206650A (en)	2019-03-14	2024-12-30	Genentech Inc	Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
BR112021018506A2 (pt)	2019-03-19	2021-11-30	Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron	Terapia de combinação para tratamento do câncer
JP7593939B2 (ja)	2019-04-19	2024-12-03	ジェネンテック，インコーポレイテッド	抗ｍｅｒｔｋ抗体及びその使用方法
BR112021020532A2 (pt)	2019-04-19	2022-03-15	Janssen Biotech Inc	Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
JP7711945B2 (ja)	2019-04-30	2025-07-23	センティバイオサイエンシズインコーポレイテッド	キメラ受容体及びその使用方法
JP7550794B2 (ja)	2019-05-14	2024-09-13	ジェネンテック，インコーポレイテッド	濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
CA3137512A1 (en)	2019-05-14	2020-11-19	Werewolf Therapeutics, Inc.	Separation moieties and methods and use thereof
AU2020275348A1 (en)	2019-05-15	2021-12-09	Chugai Seiyaku Kabushiki Kaisha	An antigen-binding molecule, a pharmaceutical composition, and a method
MX2021014932A (es)	2019-06-03	2022-04-06	Univ Chicago	Métodos y composiciones para tratar cáncer con portadores de fármacos que se enlazan al colágeno.
WO2020248065A1 (en) *	2019-06-12	2020-12-17	Ontario Institute For Cancer Research (Oicr)	Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
ES2981364T3 (es)	2019-06-17	2024-10-08	Tagworks Pharmaceuticals B V	Compuestos para liberación clic rápida y eficiente
CR20220049A (es)	2019-07-10	2022-03-02	Chugai Pharmaceutical Co Ltd	Moléculas de unión a claudina-6 y usos de las mismas
JPWO2021010326A1 (de)	2019-07-12	2021-01-21
CA3147365A1 (en)	2019-08-14	2021-02-18	Joanne LIM	Extracellular vesicle-nlrp3 antagonist
KR20220070432A (ko)	2019-08-14	2022-05-31	코디악 바이오사이언시즈, 인크.	Cebp/베타를 표적으로 하는 세포외 소포-aso 작제물
WO2021030769A1 (en)	2019-08-14	2021-02-18	Codiak Biosciences, Inc.	Extracellular vesicles with nras antisense oligonucleotides
KR20220070433A (ko)	2019-08-14	2022-05-31	코디악 바이오사이언시즈, 인크.	Stat6을 표적으로 하는 세포외 소포-aso 작제물
BR112022003635A2 (pt)	2019-09-04	2022-05-24	Pf Medicament	Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
CR20220127A (es)	2019-09-27	2022-05-27	Genentech Inc	Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
EP4017542A1 (de)	2019-10-04	2022-06-29	Tae Life Sciences	Antikörperzusammensetzungen mit fc-mutationen und ortsspezifischen konjugationseigenschaften
AU2020365836A1 (en)	2019-10-18	2022-04-28	F. Hoffmann-La Roche Ag	Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma
EP4031250A1 (de)	2019-10-22	2022-07-27	The United States of America, as represented by the Secretary, Department of Health and Human Services	Gegen b7h3 (cd276) gerichtete hochaffine nanokörper zur behandlung von multiplen soliden tumoren
CA3155922A1 (en)	2019-11-06	2021-05-14	Huang Huang	Diagnostic and therapeutic methods for treatment of hematologic cancers
CN115175926A (zh)	2019-11-14	2022-10-11	狼人治疗公司	可激活细胞因子多肽及其使用方法
US20250197819A1 (en)	2019-11-22	2025-06-19	Medimmune Limited	Fusion proteins comprising an e2 ubiquitin or ubiquitin-like conjugating domain and a targeting domain for specific protein degradation
US12570749B2 (en)	2019-12-06	2026-03-10	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to GPRC5D-targeted binding domains and related compositions and methods
CN115916817A (zh)	2019-12-06	2023-04-04	朱诺治疗学股份有限公司	针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
AU2020402752A1 (en)	2019-12-12	2022-06-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-drug conjugates specific for CD276 and uses thereof
IL293423A (en)	2019-12-13	2022-07-01	Genentech Inc	Anti-ly6g6d antibodies and methods of use
CR20220357A (es)	2019-12-27	2022-08-24	Chugai Pharmaceutical Co Ltd	Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
GB2609554B (en)	2020-01-03	2025-08-20	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
CN118949063A (zh)	2020-01-22	2024-11-15	上海森辉医药有限公司	艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
AU2021236306A1 (en)	2020-03-13	2022-09-15	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en)	2020-03-19	2024-03-05	Genentech, Inc.	Isoform-selective anti-TGFβ antibodies and methods of use
US20230241242A1 (en)	2020-03-25	2023-08-03	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Preparation method for antibody medicament conjugate
BR112022019073A2 (pt)	2020-03-25	2022-11-08	Jiangsu Hengrui Pharmaceuticals Co Ltd	Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma
EP4127724A1 (de)	2020-04-03	2023-02-08	Genentech, Inc.	Therapeutische und diagnostische verfahren für krebs
IL297541A (en)	2020-04-24	2022-12-01	Genentech Inc	Methods for using anti-cd79b immunoconjugates
WO2021222167A1 (en)	2020-04-28	2021-11-04	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021248133A1 (en)	2020-06-05	2021-12-09	Codiak Biosciences, Inc.	Anti-transferrin extracellular vesicles
EP4164693A1 (de)	2020-06-11	2023-04-19	Genentech, Inc.	Nanolipoprotein-polypeptidkonjugate und zusammensetzungen, systeme und verfahren damit
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
CA3181672A1 (en)	2020-06-18	2021-12-23	Shi Li	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN115812149A (zh)	2020-07-13	2023-03-17	基因泰克公司	用于预测多肽免疫原性的基于细胞的方法
US20230296612A1 (en)	2020-07-29	2023-09-21	Chugai Seiyaku Kabushiki Kaisha	Method for measuring pharmacokinetics of agent labeled with non-radioactive substance
KR20230095918A (ko)	2020-08-05	2023-06-29	주노 쎄러퓨티크스 인코퍼레이티드	Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
CN115836122A (zh)	2020-08-07	2023-03-21	基因泰克公司	用于预测多肽免疫原性的基于t细胞的方法
EP4192854A1 (de)	2020-08-07	2023-06-14	Genentech, Inc.	Flt3-ligandenfusionsproteine und verfahren zur verwendung
EP4210832A1 (de)	2020-09-14	2023-07-19	Vor Biopharma, Inc.	Chimäre antigenrezeptoren zur behandlung von krebs
TWI836278B (zh)	2020-10-05	2024-03-21	美商建南德克公司	用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
US20230391852A1 (en)	2020-10-26	2023-12-07	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
EP4236970A1 (de)	2020-10-27	2023-09-06	Vor Biopharma Inc.	Zusammensetzungen und verfahren zur behandlung hämatopoetischer malignitäten
MX2023005132A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
WO2022098628A2 (en)	2020-11-04	2022-05-12	Genentech, Inc.	Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
KR20230095113A (ko)	2020-11-04	2023-06-28	제넨테크, 인크.	항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
EP4251187A4 (de)	2020-11-25	2025-09-10	Xilio Dev Inc	Tumorspezifische spaltbare linker
IL303349A (en)	2020-12-02	2023-08-01	Shanghai Henlius Biotech Inc	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
MX2023007133A (es)	2020-12-17	2023-06-27	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de estos.
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
WO2022162518A2 (en)	2021-01-28	2022-08-04	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
TW202317612A (zh)	2021-03-01	2023-05-01	美商艾希利歐發展股份有限公司	用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
AU2022230384A1 (en)	2021-03-01	2023-09-07	Xilio Development, Inc.	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
US20240158503A1 (en)	2021-03-03	2024-05-16	Pierre Fabre Medicament	Anti-vsig4 antibody or antigen binding fragment and uses thereof
JP2024511319A (ja)	2021-03-09	2024-03-13	ゼンコアインコーポレイテッド	Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
WO2022232612A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024519415A (ja)	2021-04-30	2024-05-13	ピエールファーブルメディカモン	新しい安定な抗ｖｉｓｔａ抗体
WO2022228706A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
MX2023013264A (es)	2021-05-12	2023-11-30	Genentech Inc	Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
EP4342984A4 (de)	2021-05-19	2025-04-23	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur vorhersage der in-vivo-pharmazekinetik eines moleküls
JP2024521187A (ja)	2021-05-28	2024-05-28	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	ガンの治療のための組み合わせ療法
EP4155321A1 (de)	2021-06-04	2023-03-29	Chugai Seiyaku Kabushiki Kaisha	Anti-ddr2-antikörper und verwendungen davon
US20240270851A1 (en)	2021-06-09	2024-08-15	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
IL309115A (en)	2021-06-25	2024-02-01	Chugai Pharmaceutical Co Ltd	Anti-CTLA-4 antibodies
TWI879694B (zh)	2021-06-25	2025-04-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
US11807685B2 (en)	2021-08-05	2023-11-07	The Uab Research Foundation	Anti-CD47 antibody and uses thereof
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20240342282A1 (en)	2021-08-13	2024-10-17	Ludwig-Maximilians-Universität München	Anti-csf1r car expressing lymphocytes for targeted tumor therapy
CN118176213B (zh)	2021-08-27	2025-09-23	詹森生物科技公司	抗psma抗体及其用途
KR20240099150A (ko)	2021-09-06	2024-06-28	베락사 바이오테크 게엠베하	진핵생물에서의 유전자 코드 확장을 위한 신규 아미노아실-tRNA 합성효소 변이체
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
EP4412713A1 (de)	2021-10-05	2024-08-14	GlaxoSmithKline Intellectual Property Development Ltd	Kombinationstherapien zur behandlung von krebs
US20240404622A1 (en)	2021-10-08	2024-12-05	Chugai Seiyaku Kabushiki Kaisha	Method for preparing prefilled syringe formulation
JP2024541058A (ja)	2021-11-03	2024-11-06	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．	抗体の特異的共役
WO2023091887A1 (en)	2021-11-16	2023-05-25	Genentech, Inc.	Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
ES3039688T3 (en)	2021-11-25	2025-10-23	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
JP2024543916A (ja)	2021-11-25	2024-11-26	ヴェラクサバイオテックゲーエムベーハー	遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ）
KR20240119102A (ko)	2021-12-08	2024-08-06	유럽피안 몰레큘러 바이올로지 래보러토리	표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
KR20240116755A (ko)	2021-12-17	2024-07-30	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
AU2022411573A1 (en)	2021-12-17	2024-06-27	Shanghai Henlius Biologics Co., Ltd.	Anti-ox40 antibodies and methods of use
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
AU2023221765B2 (en)	2022-02-15	2024-09-19	Tagworks Pharmaceuticals B.V.	Masked il12 protein
WO2023180353A1 (en)	2022-03-23	2023-09-28	F. Hoffmann-La Roche Ag	Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
AU2022450448A1 (en)	2022-04-01	2024-10-10	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230406930A1 (en)	2022-04-13	2023-12-21	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
TW202404637A (zh)	2022-04-13	2024-02-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
US20230346862A1 (en)	2022-05-02	2023-11-02	Athanor Biosciences, Inc.	Cancer eradicating - bio-nanoparticles (ce-bnp)
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3257760A1 (en)	2022-06-07	2023-12-14	Genentech, Inc.	PROGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
WO2024015897A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023309556A1 (en)	2022-07-19	2025-01-23	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	Anti-steap1 antigen-binding molecules and uses thereof
JP2025531738A (ja)	2022-09-01	2025-09-25	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法及び診断方法
WO2024073751A1 (en)	2022-09-29	2024-04-04	Vor Biopharma Inc.	Methods and compositions for gene modification and enrichment
IL320221A (en)	2022-10-12	2025-06-01	Tagworks Pharmaceuticals B V	Strained bicyclo-nonanes
IL320355A (en)	2022-10-25	2025-06-01	Genentech Inc	Therapeutic and diagnostic methods for multiple myeloma
IL320482A (en)	2022-10-25	2025-06-01	Peptomyc S L	Combination therapy for cancer treatment
WO2024102948A1 (en)	2022-11-11	2024-05-16	Celgene Corporation	Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024129778A2 (en)	2022-12-13	2024-06-20	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
GB202219154D0 (en)	2022-12-19	2023-02-01	Metacurum Biotech Ab	Antibodies and uses thereof
WO2024153789A1 (en)	2023-01-20	2024-07-25	Basf Se	Stabilized biopolymer composition, their manufacture and use
WO2024168312A1 (en)	2023-02-09	2024-08-15	Vor Biopharma Inc.	Methods for treating hematopoietic malignancy
KR20250169530A (ko)	2023-03-10	2025-12-03	태그웍스 파마슈티컬스 비.브이.	개선된 t-링커를 갖는 트랜스-사이클로옥텐
EP4698225A1 (de)	2023-04-21	2026-02-25	GlaxoSmithKline Intellectual Property Development Limited	Auf zytotoxizität abzielende chimäre für antikörper-wirkstoff-konjugate und bispezifische antikörper
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
KR20260020419A (ko)	2023-06-07	2026-02-11	펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론	Mek 저해제를 이용한 암 치료용 조합 요법
WO2024251854A1 (en)	2023-06-07	2024-12-12	Fundació Privada Institut D'investigació Oncològica De Vall Hebron	Combination therapy with braf inhibitors for the treatment of cancer
EP4473974A1 (de)	2023-06-07	2024-12-11	Peptomyc, S.L.	Omomyc und kras-hemmern kombinationstherapie zur behandlung von krebs
IL324958A (en)	2023-06-08	2026-01-01	Genentech Inc	Macrophage signatures for diagnostic and therapeutic approaches for lymphoma
KR20260026054A (ko)	2023-06-13	2026-02-25	애드센트릭스 테라퓨틱스 잉크.	넥틴-4 단백질에 결합하는 항체 및 항체 약물 접합체 (adc)와 관련된 방법 및 조성물
US12319747B2 (en)	2023-07-03	2025-06-03	Medicovestor, Inc.	Methods of using anti-SP17 immunotherapeutics
AU2024295016A1 (en)	2023-07-20	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
CN121646574A (zh)	2023-07-27	2026-03-10	维拉克萨生物技术有限责任公司	亲水性反式环辛烯(hyTCO)化合物、含有该化合物的构建体和缀合物
EP4509142A1 (de)	2023-08-16	2025-02-19	Ona Therapeutics S.L.	Fgfr4 als target in der krebsbehandlung
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
US12364777B2 (en)	2023-10-20	2025-07-22	Medicovestor, Inc.	Homodimeric antibodies for use in treating cancers and methods of use
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
US12116410B1 (en)	2023-12-26	2024-10-15	Medicovestor, Inc.	Methods of manufacturing dimeric antibodies
US12378314B1 (en)	2024-02-02	2025-08-05	Medicovestor, Inc.	Proteins that bind folate receptor alpha including fully-human antibodies
US12240900B1 (en)	2024-02-02	2025-03-04	Medicovestor, Inc.	Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en)	2024-02-02	2025-03-25	Medicovestor, Inc.	Methods of using immunotherapeutics that bind folate receptor alpha
WO2025171238A1 (en)	2024-02-07	2025-08-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
WO2025264533A1 (en)	2024-06-17	2025-12-26	Adcentrx Therapeutics Inc.	Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026043376A1 (en)	2024-08-22	2026-02-26	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5053394A (en) *	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
EP0329184A3 (de) *	1988-02-19	1990-05-23	Neorx Corporation	Antimere und antimere Konjugation
US5028697A (en) *	1988-08-08	1991-07-02	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5006652A (en) *	1988-08-08	1991-04-09	Eli Lilly And Company	Intermediates for antibody-vinca drug conjugates
US5144012A (en) *	1988-08-08	1992-09-01	Eli Lilly And Company	Cytotoxic drug conjugates
US5094849A (en) *	1988-08-08	1992-03-10	Eli Lilly And Company	Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5045451A (en) *	1988-10-26	1991-09-03	Board Of Regents	Methods for screening antibodies for use as immunotoxins
IL93733A (en) *	1989-04-14	1996-01-19	American Cyanamid Co	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group and targeted forms thereof
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis

1994
- 1994-06-03 US US08/253,877 patent/US5773001A/en not_active Expired - Lifetime
- 1994-10-12 TW TW083109420A patent/TW394778B/zh not_active IP Right Cessation
1995
- 1995-05-26 US US08/452,164 patent/US5877296A/en not_active Expired - Lifetime
- 1995-05-31 JP JP15564495A patent/JP3650165B2/ja not_active Expired - Lifetime
- 1995-06-01 PT PT95303746T patent/PT689845E/pt unknown
- 1995-06-01 IL IL11398495A patent/IL113984A/xx not_active IP Right Cessation
- 1995-06-01 EP EP95303746A patent/EP0689845B1/de not_active Expired - Lifetime
- 1995-06-01 DK DK95303746T patent/DK0689845T3/da active
- 1995-06-01 AT AT95303746T patent/ATE223234T1/de active
- 1995-06-01 ES ES95303746T patent/ES2181752T3/es not_active Expired - Lifetime
- 1995-06-01 CA CA2150785A patent/CA2150785C/en not_active Expired - Lifetime
- 1995-06-01 DE DE69528016T patent/DE69528016T2/de not_active Expired - Lifetime
- 1995-06-01 SI SI9530554T patent/SI0689845T1/xx unknown
- 1995-06-02 NZ NZ536440A patent/NZ536440A/en not_active IP Right Cessation
- 1995-06-02 FI FI952720A patent/FI117690B/fi not_active IP Right Cessation
- 1995-06-02 NO NO19952206A patent/NO313617B1/no not_active IP Right Cessation
- 1995-06-02 NZ NZ272274A patent/NZ272274A/en not_active IP Right Cessation
- 1995-06-02 ZA ZA954570A patent/ZA954570B/xx unknown
- 1995-06-02 AU AU20449/95A patent/AU697280B2/en not_active Expired
- 1995-06-03 KR KR1019950014699A patent/KR100408376B1/ko not_active Expired - Lifetime
- 1995-06-05 US US08/462,939 patent/US5767285A/en not_active Expired - Lifetime
- 1995-06-05 US US08/461,284 patent/US5739116A/en not_active Expired - Lifetime
1997
- 1997-05-14 BR BR1101078-9A patent/BR1101078A/pt active IP Right Grant
- 1997-05-14 BR BR1100990-0A patent/BR1100990A/pt active IP Right Grant
- 1997-09-17 NZ NZ328762A patent/NZ328762A/xx not_active IP Right Cessation
2003
- 2003-01-27 CY CY0300005A patent/CY2334B1/xx unknown
2005
- 2005-01-12 JP JP2005004986A patent/JP2005139200A/ja active Pending

Also Published As

Publication number	Publication date
ATE223234T1 (de)	2002-09-15
FI952720A0 (fi)	1995-06-02
AU697280B2 (en)	1998-10-01
NZ272274A (en)	1997-11-24
US5739116A (en)	1998-04-14
JPH0848637A (ja)	1996-02-20
JP3650165B2 (ja)	2005-05-18
FI117690B (fi)	2007-01-31
ES2181752T3 (es)	2003-03-01
EP0689845B1 (de)	2002-09-04
IL113984A0 (en)	1995-10-31
NO313617B1 (no)	2002-11-04
DE69528016T2 (de)	2003-01-02
CA2150785A1 (en)	1995-12-04
BR1100990A (pt)	2002-04-02
KR100408376B1 (ko)	2004-03-09
US5877296A (en)	1999-03-02
AU2044995A (en)	1995-12-14
US5773001A (en)	1998-06-30
EP0689845A2 (de)	1996-01-03
NO952206D0 (no)	1995-06-02
KR960000234A (ko)	1996-01-25
NZ536440A (en)	2007-08-31
BR1101078A (pt)	1999-10-26
CA2150785C (en)	2010-07-06
NO952206L (no)	1995-12-04
DK0689845T3 (da)	2003-01-06
FI952720L (fi)	1995-12-04
US5767285A (en)	1998-06-16
PT689845E (pt)	2002-12-31
SI0689845T1 (en)	2002-12-31
NZ328762A (en)	2000-08-25
CY2334B1 (en)	2004-02-06
EP0689845A3 (de)	1999-08-25
ZA954570B (en)	1996-05-22
JP2005139200A (ja)	2005-06-02
TW394778B (en)	2000-06-21
DE69528016D1 (de)	2002-10-10

Legal Events

Date	Code	Title
2001-06-14	KB	Patent renewed
2001-07-24	KB	Patent renewed
2009-12-24	KB	Patent renewed
2013-06-27	KB	Patent renewed
2016-01-31	EXP	Patent expired

Publication	Publication Date	Title
IL113984A (en)	2000-09-28	Conjugates of methyltrithio cytotoxic agents compositions containing them and process for their preparation
UY23541A1 (es)	1993-06-28	Procedimiento para la preparacion de conjugados de tioeter
US20060182750A1 (en)	2006-08-17	Process for preparing stable drug conjugates
US20110166319A1 (en)	2011-07-07	Process for preparing purified drug conjugates
PT78752A (en)	1984-07-01	Improved process for preparing immunotoxin conjugates or relating thereto
BRPI0615049A2 (pt)	2011-04-26	processo para a preparação de conjugados de medicamento purificado
KR20060130552A (ko)	2006-12-19	비절단성 링커를 통해 연결된 세포결합물질 메이탠시노이드접합체를 사용한 특정세포집단 표적화 방법, 상기 접합체및 상기 접합체 생산방법
CY2355B1 (en)	2004-06-04	Method for the preparation of monomeric calicheamicin derivative/carrier conjugates.
HU9302330D0 (en)	1993-10-28	7-(substituted)-9-\|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
HU9302329D0 (en)	1993-10-28	7-(substituted)-9-\|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
YU10599A (sh)	2001-07-10	Amorfni benzotiofeni, postupak dobijanja istih i njihova farmaceutska formulacija
IL93733A0 (en)	1990-12-23	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group,and targeted forms thereof
HUT55800A (en)	1991-06-28	Process for producing anticoagulant peptides
Beck et al.	1994	In vitro activity of immunoconjugates between cisplatin and an anti-CA125 monoclonal antibody on ovarian cancer cell lines
IT1264495B1 (it)	1996-09-24	Complessi solubili in acqua di glicosaminoglicani, loro procedimento di preparazione e composizioni farmaceutiche che li contengono